Group 1: Ebola Vaccine Initiative - Merck & Co., Inc. and CEPI are launching a $30 million program to create an updated version of Merck's Ebola vaccine to make it cheaper and easier to distribute in low- and middle-income countries [2] - The partnership will focus on improving the manufacturing process of Merck's WHO-prequalified Ebola vaccine, Ervebo, which is currently complex and expensive to produce at scale [3] - Planned upgrades are expected to increase yield, extend shelf life, and allow Ervebo to be stored in standard refrigerators for several months, enhancing distribution capabilities [4] Group 2: Revenue Growth Outlook - Merck has raised its revenue forecast for new growth drivers to $70 billion by the mid-2030s, driven by the launch of additional drugs [6] - The company now expects cardiometabolic and respiratory treatments to generate about $20 billion in sales, an increase from the previous forecast of $15 billion [7] - Infectious disease drugs are projected to contribute roughly $15 billion, significantly up from an earlier estimate of $5 billion [7] Group 3: Company Overview - Merck & Co., Inc. is a global healthcare giant focused on discovering, developing, manufacturing, and marketing prescription medicines, vaccines, biologic therapies, and animal health products [8]